Evidence map›Paper›PMID 41001026›Full record

ArticleFrontiers in oncology2025

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC.

Alessandro Tubita, Sara Fancelli, Lorenzo Anela, Giulia Petroni, Enrico Caliman, Francesca Mazzoni, Federico Scolari, Brunella Napolitano, Beatrice Menicacci, Camilla Eva Comin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alessandro Tubita *Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Sara Fancelli *Oncology Unit, Careggi University Hospital, Florence, Italy.
Lorenzo AnelaDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giulia PetroniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Enrico CalimanOncology Unit, Careggi University Hospital, Florence, Italy.
Francesca MazzoniOncology Unit, Careggi University Hospital, Florence, Italy.
Federico ScolariDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Brunella NapolitanoOncology Unit, Careggi University Hospital, Florence, Italy.
Beatrice MenicacciDepartment of Health Sciences, University of Florence, Florence, Italy.
Camilla Eva CominDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Luca VoltoliniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Serena Pillozzi *Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Lorenzo Antonuzzo *Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent therapeutic advances, the adjuvant treatment of non-small cell lung cancer (NSCLC) remains a challenge. Reducing the risk of recurrence is still a concern, especially in the KRAS G12C population, for which platinum-based adjuvant chemotherapy (CT) remains the gold standard. In this study, we evaluated the efficacy, in terms of cell viability and volumetric reduction, of adding KRAS inhibitors (KRASi) sequentially or concurrently to CT in both parental (PR) and gemcitabine-resistant (GR) KRAS mutated NSCLC cell lines (SW1573 and H23). We demonstrated that KRASi added to CT (both sequential and concurrent treatment strategies) reduced cell viability in SW1573-PR and H23-PR and this effect is less evident in GR cell lines. Interestingly, in the 3D model, the concomitant use of KRASi+CT reduced spheroid volume in both PR and GR spheroids. Our results indicate that KRASi enhances the efficacy of CT in both NSCLC PR and GR cells, suggesting a potential therapeutic strategy to overcome chemoresistance in the adjuvant setting of NSCLC.

Indexed as

adjuvant chemotherapychemoresistanceKRAS inhibitors (KRASi)KRAS mutationsNSCLC

Identifiers

PMID41001026
PMCPMC12457849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.